PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

NCT03693326 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Lung Cancer Metastatic
Immunotherapy

Interventions

DRUG: PDR001

Sponsor

Asan Medical Center